179034-83-4

Usage

Uses

Used in Pharmaceutical Industry:
(6R,7R)-3-(5-Methyl-1,3,4-thiadiazol-2-ylsulfanyl)-7-(2-phenylacetamido)-3-cephem-4-carboxylic acid is used as a precursor in the development of new antibiotics for the treatment of bacterial infections. Its unique structure and potential antibacterial properties contribute to its ability to inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins, offering a possible solution to the growing issue of antibiotic resistance.
Further research is necessary to fully understand the mechanism of action and potential therapeutic applications of (6R,7R)-3-(5-Methyl-1,3,4-thiadiazol-2-ylsulfanyl)-7-(2-phenylacetamido)-3-cephem-4-carboxylic acid, as its structural complexity may lead to improved efficacy and reduced resistance compared to existing antibiotics.

Upstream product

• 92096-37-2 benzhydryl (6R,7R)-7β-[(phenylacetyl)amino]-3-[(methylsulfonyl)oxy]-3-cephem-4-carboxylate 
• 54639-48-4 (6R,7R)-benzhydryl 3-hydroxy-8-oxo-7-(2-phenylacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 
• 179034-64-1 benzhydryl 7β-(2-phenylacetamido)-3-(5-methyl-1,3,4-thiadiazol-2-yl)thio-3-cephem-4-carboxylate 

Relevant academic research and scientific papers

studies on anti-helicobacter pylori agents. Part 2: New cephem derivatives

The synthesis and optimization of the anti-Helicobacter pylori activity of a novel series of cephem derivatives are described. Introduction of thio-heterocyclic groups containing N- and S-atoms to the 3-position and phenyl or thienyl acetamido groups to the 7-position of the cephem nucleus dramatically improved the activity. From this series of derivatives, compound 13i was found to have extremely potent in vitro anti-H. pylori activity, superior therapeutic efficacy compared to AMPC and CAM, no cross-resistance between CAM or MNZ and low potential for causing diarrhea due to instability to β-lactamase. Copyright (C) 2000 Elsevier Science Ltd.

Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative

The synthesis and anti-Helicobacter pylori activity of a novel cephem derivative FR182024 (1) are described. FR182024 having a (5-methyl-1,3,4-thiadiazol-2-yl)-thio moiety at the 3-position and a phenylacetamido at the 7-position was found to have extremely potent in vitro anti-H.pylori activity, superior therapeutic efficacy to AMPC and CAM, and low potential for causing diarrhea.